MA45258A - Dérivés de la thailanstatine a, méthodes de traitement et méthodes de synthèse de ceux-ci - Google Patents
Dérivés de la thailanstatine a, méthodes de traitement et méthodes de synthèse de ceux-ciInfo
- Publication number
- MA45258A MA45258A MA045258A MA45258A MA45258A MA 45258 A MA45258 A MA 45258A MA 045258 A MA045258 A MA 045258A MA 45258 A MA45258 A MA 45258A MA 45258 A MA45258 A MA 45258A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- thailanstatine
- synthesis
- derivatives
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662347448P | 2016-06-08 | 2016-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA45258A true MA45258A (fr) | 2019-04-17 |
Family
ID=60578962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA045258A MA45258A (fr) | 2016-06-08 | 2017-06-08 | Dérivés de la thailanstatine a, méthodes de traitement et méthodes de synthèse de ceux-ci |
Country Status (8)
Country | Link |
---|---|
US (1) | US11584754B2 (fr) |
EP (1) | EP3468976A4 (fr) |
JP (1) | JP2019524650A (fr) |
AU (1) | AU2017277786A1 (fr) |
CA (1) | CA3027029A1 (fr) |
MA (1) | MA45258A (fr) |
MX (1) | MX2018015269A (fr) |
WO (1) | WO2017214423A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3037883A1 (fr) | 2016-09-23 | 2018-03-29 | Purdue Research Foundation | Agents anti-cancereux et leur preparation |
KR20220156974A (ko) | 2017-09-20 | 2022-11-28 | 주식회사 피에이치파마 | 타일란스타틴 유사체 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7825267B2 (en) * | 2006-09-08 | 2010-11-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Synthesis of FR901464 and analogs with antitumor activity |
WO2009031999A1 (fr) * | 2007-09-07 | 2009-03-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fr901464 et analogues présentant une activité antitumorale, et procédé de préparation de ces composés |
AU2012301466B2 (en) | 2011-08-27 | 2015-07-23 | Marrone Bio Innovations, Inc. | Isolated bacterial strain of the genus Burkholderia and pesticidal metabolites therefrom-formulations and uses |
CA2890569C (fr) | 2012-11-05 | 2019-03-05 | Pfizer Inc. | Analogues de spliceostatine |
AU2014353087B2 (en) * | 2013-11-19 | 2018-07-19 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
-
2017
- 2017-06-08 WO PCT/US2017/036589 patent/WO2017214423A2/fr unknown
- 2017-06-08 AU AU2017277786A patent/AU2017277786A1/en not_active Abandoned
- 2017-06-08 JP JP2018564281A patent/JP2019524650A/ja active Pending
- 2017-06-08 EP EP17811026.8A patent/EP3468976A4/fr not_active Withdrawn
- 2017-06-08 MX MX2018015269A patent/MX2018015269A/es unknown
- 2017-06-08 MA MA045258A patent/MA45258A/fr unknown
- 2017-06-08 CA CA3027029A patent/CA3027029A1/fr not_active Abandoned
- 2017-06-08 US US16/308,334 patent/US11584754B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2017277786A1 (en) | 2019-01-03 |
US11584754B2 (en) | 2023-02-21 |
EP3468976A4 (fr) | 2019-11-27 |
CA3027029A1 (fr) | 2017-12-14 |
WO2017214423A3 (fr) | 2018-01-11 |
WO2017214423A8 (fr) | 2018-04-05 |
JP2019524650A (ja) | 2019-09-05 |
MX2018015269A (es) | 2019-09-18 |
US20200024283A1 (en) | 2020-01-23 |
WO2017214423A2 (fr) | 2017-12-14 |
EP3468976A2 (fr) | 2019-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46102A (fr) | Composés de tétracycline et méthodes de traitement | |
IT201700081018A1 (it) | Trattamento di segnali elettrofisiologici | |
DK3448999T3 (da) | Oligonukleotider til behandling af øjensygdom | |
MA43374A (fr) | Méthodes de traitement de tumeurs malignes | |
DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
DK3171928T3 (da) | Stimulationsmønstre til behandling af tørt øje | |
DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
DK3777855T3 (da) | Fremgangsmåder til behandling af fibrotiske sygdomme | |
MA41119A (fr) | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique | |
DK3498278T3 (da) | Forbindelser til behandling af sygdomme relateret til DUX4-ekspression | |
DK3458052T3 (da) | Kombinationsbehandling af cancer | |
MA46524A (fr) | Composés de biphényl-sulfonamide destinés au traitement de néphropathies | |
DK3307267T3 (da) | Behandling af multipel sklerose | |
MA52216A (fr) | Méthodes de traitement de la colite ulcéreuse | |
MA42624A (fr) | Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive | |
DK3548061T3 (da) | Behandling af neurologiske sygdomme | |
DK3097085T3 (da) | Benzoxazinonderivater til behandling af hudsygdomme | |
DK3151814T3 (da) | Behandling af en hudlæsion | |
FR3023290B1 (fr) | Derives de flavaglines | |
BR112016015712A2 (pt) | método de tratamento de doenças hepáticas. | |
MA40687A (fr) | Méthodes et compositions de traitement de malformation vasculaire | |
MA50526A (fr) | Cocristaux, compositions pharmaceutiques de ceux-ci, et méthodes de traitement les impliquant | |
DK3532072T3 (da) | Behandling af glaukom | |
MA45258A (fr) | Dérivés de la thailanstatine a, méthodes de traitement et méthodes de synthèse de ceux-ci | |
DK3484475T3 (da) | 1-methylnicotinamid til behandlingen af kardiovaskulær sygdom |